口服阿布昔替尼成功治疗SAPHO综合征：一例报告
Successful treatment of SAPHO syndrome with oral abrocitinib: a case report.
作者信息
Lin Zhipeng, Piao Songyi, Zhang Rongxin, Yu Chao, Hou Zhao, Wang Aoxue
机构信息
Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China.
出版信息
J Dermatolog Treat. 2024 Dec;35(1):2437259. doi: 10.1080/09546634.2024.2437259. Epub 2024 Dec 9.
AIM
SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.
METHODS
We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies. The patient was treated with oral abrocitinib at a dosage of 100 mg daily.
RESULTS
After 3 months of treatment with abrocitinib, the patient exhibited considerable symptom improvement with no new facial lesions. The joint pain was completely relieved after abrocitinib administration for 15 months. No adverse events or recurrences were reported during the 18-month follow-up period.
CONCLUSIONS
Abrocitinib monotherapy may be a promising treatment option for patients with SAPHO syndrome.
目的
滑膜炎、痤疮、脓疱病、骨肥厚和骨炎（SAPHO）综合征是一种罕见的自身免疫性疾病，其特征为典型的皮肤病变（掌跖脓疱病和爆发性痤疮）和骨关节症状（无菌性骨髓炎和关节炎症）。本研究旨在评估Janus激酶1（JAK1）抑制剂阿布昔替尼治疗SAPHO综合征患者的疗效和安全性。
方法
我们报告了1例SAPHO综合征患者，其疾病进展加速，对传统治疗无反应。该患者接受每日100mg口服阿布昔替尼治疗。
结果
使用阿布昔替尼治疗3个月后，患者症状有显著改善，面部无新病变。服用阿布昔替尼15个月后关节疼痛完全缓解。在18个月的随访期内未报告不良事件或复发情况。
结论
阿布昔替尼单药治疗可能是SAPHO综合征患者一种有前景的治疗选择。
Zotero 插件